Stelexis Therapeutics

Stelexis Therapeutics is a private, clinical-stage biotech company pioneering first-in-class therapies for hematological malignancies with significant unmet need. The company's strategy centers on rapidly generating proof-of-concept for its lead assets, Eganelisib and STLX-2012, as monotherapies and in combinations. Led by a seasoned management team with deep hematology-oncology expertise, Stelexis is advancing a focused pipeline designed to induce remissions and prevent relapse in difficult-to-treat blood cancers.

Biology-driven targeting of novel pathways in hematological malignancies (e.g., PI3K-gamma in immuno-oncology, IL-1RAP on leukemic stem cells).

The PI3K inhibitor space is competitive, but gamma-specific inhibitors like Eganelisib are less common and target the immuno-oncology axis. IL-1RAP is a novel target in MDS/AML with limited clinical competition. Stelexis faces broad competition from numerous companies developing targeted therapies, antibody-drug conjugates, and cell therapies for myeloid malignancies.